Case Report

Successful Treatment with High-Dose Chemotherapy Followed by Autologous Stem-Cell Transplantation in a Patient with Metastatic Germ Cell Tumor

Jung Min Lee^a Byung Woog Kang^a Man-Hoon Han^b Dong Won Baek^a

^aDepartment of Hematology/Oncology, School of Medicine, Kyungpook National University Hospital, Kyungpook National University, Daegu, South Korea; ^bDepartment of Pathology, School of Medicine, Kyungpook National University Hospital, Kyungpook National University, Daegu, South Korea

Keywords

High-dose chemotherapy · Autologous hematopoietic cell transplantation · Germ cell tumor

Abstract

Although testicular germ cell tumors (GCTs) are known to curable disease even in cases with metastatic disease, patients in intermediate or poor-risk group may experience disease progression or refractory to the initial chemotherapy and needed second-line therapy. Long-term disease-free survival was unsatisfactory in relapsed/refractory patients with poor-risk factors and clinical trials for those patients are still insufficient. High-dose chemotherapy (HDCT) with stem-cell rescue may be an effective alternative for conventional chemotherapy-resistant patients who are eligible for transplantation. Herein, we present successful treatment experience with HDCT followed by autologous stem-cell transplantation in a severely ill patient with heavily pretreated metastatic GCT.

© 2021 The Author(s).

Published by S. Karger AG, Basel

Introduction

Testicular germ cell tumors (GCTs) are rare and accounts for <1% of all male tumors; however, they are the most common solid tumor in young males age <35 years old [1, 2]. GCTs are categorized into seminoma and nonseminoma. Nonseminoma is less common and more aggressive than seminoma [3]. Although GCTs are known to curable disease even with

Correspondence to:
Dong Won Baek, baekdw83@gmail.com

metastatic disease, patients in intermediate or poor-risk groups may experience disease progression or become refractory to initial chemotherapy and require second-line therapy [4]. Most patients will generally receive 4 cycles of Vinblastine/ifosfamide/cisplatin or paclitaxel/ifosfamide/cisplatin as a salvage regimen [5, 6]. However, long-term disease-free survival was unsatisfactory in relapsed/refractory patients with poor-risk factors. Likewise, clinical trials for these patients are often lacking [4, 7].

High-dose chemotherapy (HDCT) with stem-cell rescue may be an effective alternative for conventional chemotherapy-resistant patients in a transplant-eligible condition [1]. Since autologous bone marrow infusion therapy was introduced for malignant disease, HDCT followed by autologous stem-cell transplantation (ASCT) has become an important modality for patients with lymphomas, multiple myeloma, and some rare diseases [8]. Its therapeutic effects have been proven for several diseases. However, collecting enough stem cells from patients who have been heavily pretreated with cytotoxic chemotherapy and treatment-related mortality of HDCT is problematic. Herein, we present our successful treatment experience with HDCT followed by ASCT in a young, very sick male with chemoresistant metastatic GCT.

Case Presentation

In November 2018, a 35-year-old male visited our hospital with aggravating cough, hoarseness, and hemoptysis. From a chest computed tomography scan, a huge mediastinal mass with multiple lung nodules and enlarged lymph nodes were identified. At admission to the oncology department, the patient's general condition was good, with an Eastern Cooperative Oncology Group performance status of 1. Likewise, he did not have any specific disease history. Laboratory investigations showed meaningful data, with elevated lactate dehydrogenase, α -fetoprotein, and β -human chorionic gonadotropin (Table 1). The patient underwent a neck lymph node excisional biopsy, and histology revealed a metastatic embryonal carcinoma, a nonseminomatous type GCT (Fig. 1).

Multiple metastases, including the testes, were identified by a positron emission tomography-CT scan. As a first-line therapy, he received an etoposide, ifosfamide, and cisplatin combination regimen (VIP) to treat stage IIIC (cTxN3M1bS3) GCT. Right after the first VIP cycle, the patient developed respiratory failure due to a huge mediastinal mass compressing the bronchus. He was moved onto a ventilator until the end of the second VIP therapy. However, 2-VIP cycles were ineffective. After 4 cycles of TIP regimen as a second-line therapy, partial responses were identified and he underwent right radical orchiectomy with vasectomy in May 2019.

Table 1. Contemporaneous laboratory investigations

Marker (normal range)	Nov 2018 diagnosis	Jan 2019 after 2-VIP cycles	May 2019 after 4-TIP cycles	Sep 2019 after auto-SCT	Mar 2020 6 months	Sep 2020 12 months
LDH, U/L (≤ 250)	419	138	157	154	171	196
AFP, ng/mL (≤ 7)	2,345	10.6	5.54	6.08	3.12	3.76
β -hCG, mIU/mL (< 1)	$> 200,000$	45	6.4	1.8	< 1	< 1

AFP, α -fetoprotein; auto-SCT, autologous stem-cell transplantation; β -hCG, beta-human chorionic gonadotropin; LDH, lactate dehydrogenase; TIP, paclitaxel/ifosfamide/cisplatin; VIP, etoposide, ifosfamide, and cisplatin combination.

To prolong long-term survival without disease progression, the patient received HDCT with 700 mg/m² carboplatin plus 750 mg/m² etoposide for 3 days, followed by autologous stem-cell rescue (CD34+ stem-cell dose: 1.77 × 10⁶/kg) in September 2019. After ASCT, he has been in good general condition without relapse and is maintaining normalized lactate dehydrogenase, α-fetoprotein, and β-human chorionic gonadotropin levels (Table 1; Fig. 2). Informed consent for publication was obtained from the patient.

Discussion

The International Germ Cell Cancer Collaborative Group established a prognostic factor-based staging system for metastatic germ cell cancers, and >40% of patients in poor prognostic group would have disease relapse or be refractory to the platinum-based chemotherapy [4]. Furthermore, the International Prognostic Factors Study Group for metastatic GCTs classified patients who experienced treatment failures with first-line chemotherapy into 5 prognostic groups; the 2-year progression-free survival and 3-year overall survival of the very high-risk group were 5.6 and 6.1%, respectively [7]. Our patient corresponded to the very high-risk group and was refractory to conventional-dose chemotherapy (CDCT), thereby needing a more effective salvage therapy.

Since ASCT for GCT was introduced with high-dose carboplatin in 1986 [9], carboplatin plus etoposide-based HDCT with stem-cell rescue has improved the outcomes of relapsed/refractory GCT patients [1, 10, 11]. Einhorn et al. [1] demonstrated that metastatic GCT was curable by HDCT followed by ASCT, even when this regimen was used as a third-line or later therapy, or in patients with platinum-refractory disease. In a retrospective analysis of CDCT versus HDCT as first salvage treatments in metastatic GCT, patients treated with HDCT showed superior survival outcomes when compared with patients with CDCT [11]. According to data from 2,395 GCT patients at the Center for International Blood and Marrow Transplant Research, 49% of patients had intermediate/poor-risk disease based on the International Germ Cell Cancer Collaborative Group classification, and 29% had platinum-resistant/refractory disease. From multivariate analyses, residual disease at the time of transplantation, >1 line of chemotherapy before HDCT, and nonseminoma were associated with inferior long-term outcomes. In contrast, HDCT as the first salvage therapy and tandem transplantation may be beneficial for patients with unfavorable factors [12].

Although HDCT with ASCT showed benefits for high-risk metastatic GCT patients, CDCT remains the preferred approach for first-line salvage in many centers due to issues with adequate stem-cell collection (the optimal stem-cell dose for transplantation is ≥8 × 10⁶ CD34+ cells/kg) and transplantation-related mortality [12, 13]. Hamid et al. [14] recently reported that plerixafor played a role in stem-cell mobilization for relapsed GCT. Moreover, improvements in supportive care after HDCT may reduce nonrelapse mortality after transplantation [12].

Fig. 1. Neck lymph node histology at the time of diagnosis showing representative features and immunohistochemical findings. **a** Embryonal carcinoma shows necrosis (black arrowheads), hemorrhage (white arrow), and fibrosis (black arrows, surrounding tumor cells in a linear pattern) (**a** ×12.5 HE). **b** Embryonal carcinoma characterized by various histological patterns: tubular patterns (**b** ×100 HE). **c** papillary patterns (**c** ×100 HE), and **d** solid patterns (**d** ×100 HE). **e** Bizarre tumor cells, marked pleomorphism, vesicular nuclei, and prominent nucleoli are observed (**e** ×200 HE). **f** Immunohistochemical findings of positive staining for cytokeratin (**f** ×200), **g** CD30 (**g** ×200), and **h** PLAP (**h** ×200).

(For figure see next page.)

Fig. 2. **a** Chest CT scan at the time of diagnosis in November 2018 showing a huge mediastinal mass and multiple lung nodules. **b** Positron emission tomography scan at the time of diagnosis in November 2018. Increased fluorodeoxyglucose uptake was identified in the right testis, mediastinum, and multiple lymph nodes. **c** A chest CT scan after 4 cycles of paclitaxel/ifosfamide/cisplatin showing a partial response. **d** A recent chest CT scan in December 2020. The mediastinal mass was dramatically reduced after ASCT, and an impressive response was maintained without progression. TIP, paclitaxel/ifosfamide/cisplatin; ASCT, autologous stem-cell transplantation; CT, computed tomography; PET, positron emission tomography; FDG, fluorodeoxyglucose.

At present, a carboplatin plus etoposide-based regimen is considered an optimal conditioning regimen [10, 12]. Therefore, HDCT followed by ASCT should be actively recommended to relapsed/refractory high-risk GCT patients.

Statement of Ethics

Written informed consent for publication of this case report was obtained from the patient. This study was approved by the Institutional Review Board of Kyungpook National University Hospital (IRB No. KNUH 2021-03-011).

Conflict of Interest Statement

The authors have no conflicts of interest to declare.

Funding Sources

This research received no external funding.

Author Contributions

Byung Woog Kang and Dong Won Baek conceived of the presented idea. Byung Woog Kang, Dong Won Baek, and Jung Min Lee were involved in management of the patient. Man-Hoon Han carried out the diagnosis of the tumor. All the authors read and approved the final manuscript.

References

- 1 Einhorn LH, Williams SD, Chamness A, Brames MJ, Perkins SM, Abonour R. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. *N Engl J Med*. 2007;357:340–8.
- 2 Pishgar F, Haj-Mirzaian A, Ebrahimi H, Saeedi Moghaddam S, Mohajer B, Nowroozi MR, et al. Global, regional and national burden of testicular cancer, 1990–2016: results from the Global Burden of Disease Study 2016. *BJU Int*. 2019;124:386–94.
- 3 Vasdev N, Moon A, Thorpe AC. Classification, epidemiology and therapies for testicular germ cell tumours. *Int J Dev Biol*. 2013;57:133–9.
- 4 Mead GM, Stenning SP, Cook P, Fossa SD, Horwich A, Kaye SB, et al. International germ cell consensus classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. *J Clin Oncol*. 1997;15(2):594–603.
- 5 National Comprehensive Cancer Network. *National comprehensive cancer network clinical practice guidelines in oncology (NCCN®): testicular cancer. Version 1.2021*. Fort Washington, PA: National Comprehensive Cancer Network Inc.; 2021. Available from: https://www.nccn.org/professionals/physician_gls/pdf/testicular.pdf.
- 6 Oldenburg J, Fosså SD, Nuver J, Heidenreich A, Schmoll HJ, Bokemeyer C, et al. Testicular seminoma and non-seminoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2013;24(Suppl 6):vi125–32.
- 7 Lorch A, Lorch A, Beyer J, Bascoul-Mollevi C, Kramar A, Einhorn LH, et al. Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. *J Clin Oncol*. 2010;28:4906–11.
- 8 Gratwohl A, Balmonte H, Aljurf M, Pasquini MC, Bouzas LF, Yoshimi A, et al. Hematopoietic stem cell transplantation: a global perspective. *JAMA*. 2010;303:1617–24.
- 9 Nichols CR, Tricot G, Williams SD, Besien KV, Loehrer PJ, Roth BJ, et al. Dose-intensive chemotherapy in refractory germ cell cancer: a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. *J Clin Oncol*. 1989;7:932–9.
- 10 Feldman DR, Sheinfeld J, Bajorin DF, Fischer P, Turkula S, Ishill N, et al. TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis. *J Clin Oncol*. 2010;28:1706–13.
- 11 Lorch A, Bascoul-Mollevi C, Kramar A, Einhorn L, Necchi A, Massard C, et al. Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database. *J Clin Oncol*. 2011;29:2178–84.
- 12 Kilari D, D'Souza A, Fraser R, Qayed M, Davila O, Agrawal V, et al. Autologous hematopoietic stem cell transplantation for male germ cell tumors: improved outcomes over 3 decades. *Biol Blood Marrow Transplant*. 2019;25(6):1099–106.
- 13 Sezer O, Possinger K, Metzner B, Illiger HJ, Wattad M, Heit W, et al. Optimal CD34+ cell dose in autologous peripheral-blood stem-cell transplantation. *J Clin Oncol*. 2000;18:3319–20.
- 14 Hamid AA, Markt SC, Vicier C, McDermott K, Richardson P, Ho VT, et al. Autologous stem-cell transplantation outcomes for relapsed metastatic germ-cell tumors in the modern era. *Clin Genitourin Cancer*. 2019;17(1):58–e1.